ESMO

ESMO 2019


Expert interviews at ESMO 2019


Filippo de Braud explains what can be achieved with TRK inhibition in TRK-fusion-positive NSCLC, indirectly compares the performance of entrectinib to crizotinib in ROS1-positive disease and shares his opinion on the intracranial activity of entrectinib.


Michael Duruisseaux gives an overview on the role of NRG1 gene fusion in the tumorigenesis of lung cancer, the clinical experience with targeted treatment and the importance of molecular testing with respect to NRG1 fusions.


Stephen Liu on the latest insights in the field of ALK-targeted treatment in lung cancer, a recent update on the clinical evaluation of NRG1-directed therapies, as well as novel molecular targets for lung cancer treatment in the foreseeable future.


Ioannis Metaxas talks about the rationale for the evaluation of lurbinectedin in malignant pleural mesothelioma, the clinical results with lurbinectedin in patients with mesothelioma to date and other areas of lung cancer treatment in which lurbinectedin might prove useful in the future.

ESMO 2018

Expert interviews at ESMO

 

Click on the button to load the content from bit.ly.

Load content

Dr. Sanjay Popat talks about modern chemotherapeutic treatment options for patients with squamous NSCLC, the benefits of combining immunotherapies with chemotherapy and the use of liquid biopsy for metastatic NSCLC in clinical practice today.

Click on the button to load the content from playout.3qsdn.com.

Load content

Dr. Luis Paz-Ares explains new principles of treatment using bifunctional fusion proteins, their advantages compared to the existing therapies and preliminary results in NSCLC patients.

ESMO 2017

English

Congress Report ESMO 2017

Highlights include the latest clinical trial results for the PD-L1 inhibitors atezolizumab and durvalumab, new data for the PD-1 inhibitor nivolumab and the toll-like receptor 9 agonist lefitolimod; a discussion of the optimal succession of targeted agents across several treatment lines for both EGFR and ALK positive disease; positive data for combined dabrafenib/trametinib therapy for BRAF-positive lung cancer patients; and lots more besides.

Mandarin

Japanese

Expert interviews at ESMO

 

Click on the button to load the content from playout.3qsdn.com.

Load content

Hossein Borghaei discusses the latest immunotherapeutic treatment options to emerge for lung cancer at the 2017 ESMO congress.

Click on the button to load the content from playout.3qsdn.com.

Load content

Nicolas Girard on the sequencing of targeted agents against EGFR positive NSCLC, and further considerations for treatment of the disease including side effects and possible combination therapies.

Click on the button to load the content from playout.3qsdn.com.

Load content

Lecia Sequist on how best to treat oncogene-driven oligometastatic lung cancer, given progression through multiple lines of treatment.

Click on the button to load the content from playout.3qsdn.com.

Load content

Filippo de Marinis on the latest data from the OAK trial studying the PD-L1 antibody atezolizumab that was presented at the 2017 ESMO congress, including efficacy within particular patient subgroups, and tolerability.

 


ESMO 2016 Copenhagen

English

Spanish

Mandarin

Expert interviews at ESMO

Click on the button to load the content from playout.3qsdn.com.

Load content

Enriqueta Felip on the treatment of RET- and ROS1-rearrangement positive lung cancer.

Click on the button to load the content from playout.3qsdn.com.

Load content

Martin Reck discusses the management of immunotherapy related adverse events.

Click on the button to load the content from playout.3qsdn.com.

Load content

Pasi A. Jänne talks chemotherapy, biomarkers, and molecular targeted therapies.

Click on the button to load the content from playout.3qsdn.com.

Load content

Anders Mellemgaard on anti-angiogenesis treatments